� The results of the TRANSCEND� trial shew that Micardis� 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving topper standard of care (p=0.048), referring to the same termination as that defined as the primary endpoint of the landmark HOPE trial published in 2000.1,2 Therapy with telmisartan was considerably tolerated and showed a trend towards a lower rate of discontinuation.1
The new data on 5,926 patients from 40 countries were presented today at the annual meeting of the European Society of Cardiology (ESC) in Munich, Germany. TRANSCEND� (Telmisartan Randomised AssessmeNt Study in ACE-iNtolerant subjects with cardiovascular Disease) is the first landmark trial to test and prove the cardiovascular protective effects of an hypertensin II receptor blocker (ARB) - Boehringer Ingelheim's telmisartan - versus placebo, on top of standard therapy (including anti-hypertensives, anti-platelet therapy and statins), in bad individuals wHO cannot tolerate an hypertensin converting enzyme (ACE)-inhibitor.
An 8% simplification of events in the pre-specified primary endpoint made up of the composite of cardiovascular death, myocardial infarction, cerebrovascular accident and hospitalization for congestive heart failure was seen in the trial, which was statistically non-significant with a p-value of 0.216 (HR 0.92).1 Translated into absolute figures, only 465 patients in the telmisartan limb experienced a cardiovascular event versus 504 patients receiving placebo on top of current c. H. Best standard of care.
All cardiovascular hospitalisations were significantly reduced with telmisartan (894 vs 980; p=0.025). In general, the data show that the protective effects of telmisartan were more pronounced the yearner patients were on treatment.1
"Earlier this year, the ONTARGET� Trial showed that telmisartan is as protective as, but better tolerated than the ACE-inhibitor ramipril. The TRANSCEND� results represent a moderate just important stride forward for high-risk patients who cannot tolerate an ACE-inhibitor," commented Professor Salim Yusuf, lead investigator of the ONTARGET� Trial Programme and Director of the Population Health Research Institute at McMaster University, Hamilton, Canada.
Commenting on the implications of the results for general practitioners, Dr Sarah Jarvis, Richford Gate Medical Practice, London, said "Until now, physicians treating ACEI-intolerant patients at risk of exposure of ticker attack or stroke did not have a proved alternative to the ACE-inhibitor ramipril - a office we faced with one in five high peril patients. We now have the scientific evidence to show that telmisartan protects patients ACEI-intolerant patients against heart attack, stroke and cardiovascular death while screening a placebo-like tolerability. This builds on previous findings of the ONTARGET � trial and gives physicians the confidence of prescribing a do drugs with proven efficacy that will be taken as prescribed and not left in the drawer."
TRANSCEND� included a broad cross section of cardiovascular high risk patients (patients older than 55 years, who get had myocardial infarction, peripheral arterial stop disease, stroke or transient ischaemic attacks or suffer from diabetes mellitus and additional risk factors).
The trial, a parallel report to the ONTARGET� trial3, which together form the ONTARGET� Trial Programme, investigated the personal effects of telmisartan 80mg in 5,926 patients intolerant to widely-prescribed ACE-inhibitors. Worldwide, 10-39% of patients with hypertension are intolerant to ACE-inhibitors4-6 which often leads to discontinuation of treatment leaving patients unprotected. Side effects associated with ACE-inhibitors include intolerable cough and rare, merely potentially life threatening, quincke's edema.4-6
Also of promissory note, the risk of exposure reduction of 13% with telmisartan was achieved despite a high gear proportion of patients receiving proven therapies such as statins, antiplatelet agents or betablockers.
"While cardiovascular treatment has improved substantially over the last ten years, telmisartan still further reduced cardiovascular risk of exposure. We are proud to have advanced medical knowledge in the cardiovascular sports stadium with our landmark studies ONTARGET� and the parallel of latitude trial TRANSCEND�. We receive followed nigh 50,000 telmisartan patients in clinical trials in the final 5 eld, and at present have have from everyday use of telmisartan summing up to 25 one thousand thousand patient age all over the existence. This makes the medication one of the best-researched cardiovascular drugs with an outstanding efficacy and safety/tolerability profile, " commented Dr Andreas Barner, vice chairman of the Board of Managing Directors of Boehringer Ingelheim, responsible for Research, Development and Medicine.
Cardiovascular disease (CVD) is the leading effort of death worldwide, causing over 17.5 jillion deaths per year.7 7.6 million people die from a heart attack and 5.7 million die from a stroke every year.7 Global deaths from CVD are predicted to reach approximately 25 million by 2020.8 CVD is also currently a star cause of disability, and is predicted to be the largest cause of disability world-wide by 2020.8 A major stroke is viewed by more than half of those at risk of exposure as being worse than death.9
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be mindful that at that place may be national differences between countries regarding specific medical information, including commissioned uses. Please take score of this when referring to the information provided in this document. This press release is non intended for distribution within the U.S.A.
About telmisartan (Micardis�/Kinzal�/Pritor�)
Telmisartan is a modern member of the Angiotensin II Receptor Blocker (ARB) class and is being investigated in the about ambitious and far-reaching research programme conducted with an ARB. In the clinical trial programmes ONTARGET�, PROTECTION� and PRoFESS� over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of telmisartan (for more information please visit
http://www.news-landmarktrials.com ).
Telmisartan was discovered and developed by Boehringer Ingelheim. Under the trademarks Micardis� and MicardisPlus� (combination with hydrochlorothiazide) the company markets telmisartan in 84 countries around the world, including the USA, Japan and European countries. Telmisartan is marketed in cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in selected markets.
Astellas Pharma Inc. co-promotes telmisartan under the trademark Micardis�, Bayer HealthCare promotes telmisartan below the brand names Kinzalmono�, Kinzalkomb� (combination with hydroDIURIL), and Pritor� and PritorPlus� (combination with hydrochlorothiazide) in markets across Europe. Pritor�, and PritorPlus� is as well marketed by GlaxoSmithKline in selected markets.
The sponsor of the ONTARGET� Trial Programme is Boehringer Ingelheim; co-funders in selected countries are Bayer HealthCare and GlaxoSmithKline.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high school therapeutic value for human and veterinarian medicine.
In 2007, Boehringer Ingelheim posted net gross sales of 10.9 billion euro piece spending peerless fifth of net gross revenue in its largest business segment Prescription Medicines on research and development.
Related links:
Boehringer Ingelheim press tamp - European Society of Cardiology Congress 2008 (ESC)
Ontarget-Telmisartan website (for Healthcare Professionals outside the PLC191% only)
Micardis� website (for Healthcare Professionals outside the U.S. only if)
References:
1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in bad patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled tryout. Lancet Published online 31 August 2008.
2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an
Tuesday 2 September 2008
Saturday 23 August 2008
Iran bans actress from leaving over Hollywood role
Iran has banned a popular actress from leaving the country after she starred in a Hollywood movie without permission from Iranian regime, the official IRNA news agency reported.
The ban was imposed afterward Golshifteh Farahani, 25, took part in Ridley Scott's Body of Lies with Leonardo DiCaprio and Russell Crowe.
Farahani is the low Iranian-based female actor to star in a Hollywood movie.
"She establish out about the ban on Tuesday when she wanted to travel to Hollywood to examine a new offer," an unidentified source told the agency.
IRNA said Iranian movie stars must find permission from the Culture Ministry before appearing in foreign movies.
Body of Lies, expected to be released in October, is the story of an agent who travels to Jordan to track down an al Qaeda leader.
Farahani won the 2006 Golden Seashell at the San Sebastian International Film Festival for her character in Iranian director Bahman Ghobadi's picture show Half Moon.
She also starred in Santuri, an Iranian film whose release was delayed for several months while censors debated whether it should be prohibited, a common fate of many Iranian movies and of most Western films deemed to a fault provocative for the Iranian public.
International film festivals accept become an important way out for Iranian film makers whose work is often censored at home.
More information
Wednesday 13 August 2008
Wynn: Hooker, I Hardly Knew Her!
Steve Wynn is intuitive feeling hurt. And when Wynn gets hurt, he hurts back -- in court.
Joe Francis just found that out the hard way. The "Girls Gone Wild" porntrepreneur just got sued -- again -- by Wynn, this time for defamation. Joe had alleged in that baller of a suit last week that Wynn Las Vegas lures big big spenders using "alcohol, prostitutes and illegal drugs."
Wynn wants in excess of $10K from Francis for that (although we're guessin' it'll be a ton more than that), in addition to the $2 mil he already sued Francis for over unpaid gambling debts.
So far, no comment from Francis...but the day is young.
More info
Joe Francis just found that out the hard way. The "Girls Gone Wild" porntrepreneur just got sued -- again -- by Wynn, this time for defamation. Joe had alleged in that baller of a suit last week that Wynn Las Vegas lures big big spenders using "alcohol, prostitutes and illegal drugs."
Wynn wants in excess of $10K from Francis for that (although we're guessin' it'll be a ton more than that), in addition to the $2 mil he already sued Francis for over unpaid gambling debts.
So far, no comment from Francis...but the day is young.
More info
Wednesday 6 August 2008
Givin' 'em the Slipknot
While many rock stars spend their downtime musing when to order room service, Slipknot percussionist Shawn �Clown� Crahan spends his days working feverishly to make sure his hydraulic drum riser won�t shot in midair and plunge him to yet some other near-death injury.
Such is life when you�re in a maniacal syndicate that currently has one member in a wheelchair because he broke both heels saltation off a riser.
�One wrong move and uh-oh, Slipknot fashion,� said Crahan, who�s besides known as #6 of the niner masked alloy masters. �Nothing in Slipknot is safe.�
The agonizing injury to Sid �#0� Wilson occurred in Washington during the first base show of the Iowa-based band�s run on the Rockstar Mayhem Fest, which pulls into Mansfield�s Comcast Center tomorrow.
The injury hasn�t slowed either Sid or the band. In fact, when the Herald caught up with Crahan by phone from St. Louis, the keg-slamming percussionist was desperately operative with his crew to reinforce the welding on his drum lift. The reason? The previous night, Sid hung from it and it nearly broke off, which would give likely plummeted both musicians to farther injuries.
�Sid was crawling on it and it bent forward, and I could feel it. If we had been on it anymore, I think we would get been done,� Crahan said.
Live, Slipknot is a seizure-inducing spectacle. But peradventure even more impressive is the fact that the Grammy-winning stripe has retained the like nine members for almost a decade.
�We have an unwritten swearing that would never be understood by anybody around what we do and what we are,� Crahan explained. �It�s like this goliath self-experiment on tolerance.�
Rumors of the band�s demise are constantly swirling, largely fueled by the success of singer Corey Taylor�s early platinum-selling band, Stone Sour, and other members� english projects. But every twosome of age they come in back stronger than ever, and with redesigned versions of their horror-flick-inspired masks. The band�s latest album, �All Hope Is Gone� (Roadrunner), comes out afterward this month and if the blistering first individual �Psychosocial� is any indication, it�ll be one of metal�s c. H. Best this year.
�It�s an ongoing journey. It�s just another constellation in the nine-point star of Slipknot,� Crahan said of the new record.
As for the gruelling - and frequently afflictive - life on the road, he added: �If it wasn�t for the god of music, I wouldn�t be able to get out there. I love it. As much as I hate it sometimes, I love it.�
More info
Thursday 26 June 2008
Wednesday 18 June 2008
MIA Cancels Her Forthcoming UK Tour
MIA has axed her UK tour and she made the announcement while performing at the MoMa venue in New York this week (on June 9th).
"This is my last show. I cancelled the UK tour. Nobody knows. This is it. You're hearing it first. My manager was supposed to cancel it yesterday, but he was watching football � don't tell anyone - and he forgot. So nobody knows. I guess now they will." MIA told New York Magazine.
"I'm cancelling because I feel like physically I just have to stop for a second. It's too insane. I was losing a sense of just, like, reality, you know what I mean? I think for an artist like me, it's so important for me to be in the streets and go to the same shop every day and see the same people and, like, communicate."
"And it's really difficult to do that when you're in the city every day for 24 hours. Like, I love connecting with my band, but I want to actually help them and be a part of peoples' lives. Which is really hard when you're on tour."
MIA also added that she will still be working on her next album - "I've been writing on tour. I'm really into writing new songs. I'm going to put out a new record instead. At the end of the day, I'm here, you know."
See Also
Monday 9 June 2008
Angelina Jolie: 'Brad Pitt Finds My Pregnancy Sexy'
Angelina Jolie has revealed that husband Brad Pitt finds her pregnancy “sexy.”
Rumours surfaced on Friday that the couple has already welcomed their twins into the world - although their rep insisted the reports are premature.
It seems that, for now, Angie is enjoying being a mommy-to-be.
“I love it. It makes me feel like a woman. It makes me feel that all the things about my body are suddenly there for a reason," she gushes in the new issue of Vanity Fair.
"It makes you feel round and supple, and to have a little life inside you is amazing."
According to the actress, Brad has also played a part in helping her to appreciate her blooming figure.
She adds, "Also, I’m fortunate. I think some women have a different experience depending on their partner. I think that affects it. I happen to be with somebody who finds pregnancy very sexy. So that makes me feel very sexy.”
Rumours surfaced on Friday that the couple has already welcomed their twins into the world - although their rep insisted the reports are premature.
It seems that, for now, Angie is enjoying being a mommy-to-be.
“I love it. It makes me feel like a woman. It makes me feel that all the things about my body are suddenly there for a reason," she gushes in the new issue of Vanity Fair.
"It makes you feel round and supple, and to have a little life inside you is amazing."
According to the actress, Brad has also played a part in helping her to appreciate her blooming figure.
She adds, "Also, I’m fortunate. I think some women have a different experience depending on their partner. I think that affects it. I happen to be with somebody who finds pregnancy very sexy. So that makes me feel very sexy.”
Subscribe to:
Posts (Atom)